PEP

ASGE Journal ScanPancreas

Pure Cut Current for Biliary Sphincterotomy Is Associated With Less Delayed Bleeding and May Reduce Post-ERCP Pancreatitis Risk

Pure Cut Current for Biliary Sphincterotomy Is Associated With Less Delayed Bleeding and May Reduce Post-ERCP Pancreatitis Risk

Thermal injury from biliary sphincterotomy is thought to play a role in at least a proportion of post-ERCP pancreatitis (PEP) cases. Thus, the present study

ASGE Journal ScanPancreas

True Rate of Post-ERCP Pancreatitis: Do Randomized Trials Provide the Answer?

True Rate of Post-ERCP Pancreatitis: Do Randomized Trials Provide the Answer?

Pancreatitis after ERCP is one of the most common and morbid adverse events following any gastrointestinal endoscopy procedure. It is imperative that the consent process

ASGE Journal ScanPancreas

On Balance, Benefit of Sphincterotomy for Biliary Stenting Appears to Outweigh the Risk

On Balance, Benefit of Sphincterotomy for Biliary Stenting Appears to Outweigh the Risk

Limited reports have suggested that endoscopic biliary sphincterotomy (ES) at the time of transpapillary biliary stent placement may reduce the risk of post-ERCP pancreatitis (PEP).

ASGE Journal ScanPancreas

Further Evidence Supporting Early, Primary Use of Precut Sphincterotomy for Duct Access

Further Evidence Supporting Early, Primary Use of Precut Sphincterotomy for Duct Access

Deep access to the bile duct or the pancreatic duct is required in order to complete all subsequent therapeutic ERCP maneuvers. Precut sphincterotomy (PCS) refers

ASGE Journal ScanPANCREATOBILIARY

Prophylaxis for Post-ERCP Pancreatitis Appears Underutilized

Prophylaxis for Post-ERCP Pancreatitis Appears Underutilized

Post-ERCP pancreatitis (PEP) remains an important adverse event. Indomethacin suppositories and pancreatic duct (PD) stents have both been demonstrated to reduce PEP in patients at

ERCPLiteraturePancreas

NSAIDs against post-ERCP pancreatitis – any doubts ?

NSAIDs against post-ERCP pancreatitis – any doubts ?

The application of non-steroidal anti-inflammatory drugs (NSAIDs) such as indometacin or diclofenac to prevent post-ERCP pancreatitis (PEP) has been examined in several randomized trials throughout